Treatment response, survival, and safety profile of camrelizumab plus apatinib regimen as third-line treatment in metastatic gastric cancer patients
- Resource Type
- Article
- Source
- In
Clinics and Research in Hepatology and Gastroenterology August-September 2022 46(7) - Subject
- Language
- ISSN
- 2210-7401